ImmuCell Preliminary Q4 Sales Rise, Production Exceeds Capacity, Backlog Reduced

MT Newswires Live
01/10

ImmuCell (ICCC) reported preliminary Q4 sales late Thursday of $7.8 million, up from $5.1 million a year earlier.

The full-year total sales stand at $26.5 million, up from $17.5 million in 2023, according to the company.

Analyst estimates were not available for comparison.

ImmuCell said its annualized production for the quarter ended Dec. 31 was about 103% of estimated full capacity and helped reduce its orders backlog to $4.4 million as of Jan. 1, from $9.4 million as of Jan. 1, 2024.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10